Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 8, 2011, Pages 519-524

  Gonzalez Fierro, A ^a   Vasquez Bahena, D ^a   Taja Chayeb, L ^a   Vidal, S ^a   Trejo Becerril, C ^a   Perez Cardenas E ^a   De La Cruz Hernandez E ^a   Chavez Blanco A ^a   Gutierrez O ^a   Rodriguez, D ^b   Fernandez, Z ^b   Duenas Gonzalez A ^c  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^b SA de C V   (Mexico)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acetylator phenotype; Epigenetics; Hydralazine; Pharmacokinetics

Indexed keywords

HYDRALAZINE; IBUPROFEN;

ACETYLATOR PHENOTYPE; ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL EVALUATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DNA METHYLATION; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG HALF LIFE; EPIGENETICS; FAINTNESS; FEMALE; HEADACHE; HEART ATRIUM FLUTTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; SINGLE DRUG DOSE; SINUS TACHYCARDIA; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER;

ACETYLATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; DELAYED-ACTION PREPARATIONS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDRALAZINE; MALE; NEOPLASMS; PHENOTYPE; TABLETS; YOUNG ADULT;

EID: 80052216583     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201526     Document Type: Article

References (39)

1. Magee LA, Cham C, Waterman EJ, Ohlsson A, von Dadelszen P. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003; 327: 955-960. doi:10.1136/bmj.327.7421.955 PubMed (Pubitemid 37330398)
2. Ramsay LE, Silas JH, Ollerenshaw JD, Tucker GT, Phillips FC, Freestone S. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension? Eur J Clin Pharmacol. 1984; 26: 39-42. doi:10.1007/BF00546706 PubMed
3. Jounela AJ, Pasanen M, Mattila MJ. Acetylator phenotype and the antihypertensive response to hydralazine. Acta Med Scand. 1975; 197: 303-306. doi:10.1111/j.0954-6820.1975.tb04922.x PubMed
4. Strandberg I, Boman G, Hassler L, Sjöqvist F. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome. Acta Med Scand. 1976; 200: 367-371. doi: 10.1111/j.0954-6820.1976.tb08248.x PubMed
5. Johnston GD. Dose-response relationships with antihypertensive drugs. Pharmacol Ther. 1992; 55: 53-93. doi: 10.1016/0163-7258(92)90029Y PubMed
6. Garcia-Manero G. Demethylating agents in myeloid malignancies. Curr Opin Oncol. 2008; 20: 705-710. doi:10.1097/CCO.0b013e328313699c PubMed
7. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA. 1997; 94: 4681-4685. doi:10.1073/pnas.94.9.4681 PubMed
8. Stopper H, Körber C, Gibis P, Spencer DL, Caspary WJ. Micronuclei induced by modulators of methylation: analogs of 5-azacytidine. Carcinogenesis. 1995; 16: 1647-1650. doi:10.1093/carcin/16.7.1647 PubMed
9. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature. 1977; 267: 364-366. doi:10.1038/267364a0 PubMed
10. Beisler JA. Isolation, characterization, and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem. 1978; 21: 204-208. doi:10.1021/jm00200a012 PubMed
11. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, Baker SD, Zhao M, Weber JS. Phase I trial of continuous infusion 5-aza-2′- deoxycytidine. Cancer Chemother Pharmacol. 2003; 51: 231-239. PubMed
12. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox A, Hong JA, Chen GA, Pishchik V, Figg WD, Murgo AJ, Steinberg SM. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006; 12: 5777-5785. doi:10.1158/1078-0432.CCR-060669 PubMed (Pubitemid 44629609)
13. Gollob JA, Sciambi CJ, Peterson BL, Richmond T, Thoreson M, Moran K, Dressman HK, Jelinek J, Issa JP. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res. 2006; 12: 4619-4627. doi:10.1158/1078-0432.CCR-060883 PubMed (Pubitemid 44297813)
14. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs. 2002; 3: 627-633. PubMed
15. Arce C, Segura-Pacheco B, Perez-Cardenas E, Taja-Chayeb L, Candelaria M, Dueñnas-Gonzalez A. Hydralazine target: from blood vessels to the epigenome. J Transl Med. 2006; 4: 10. doi:10.1186/1479-5876-4-10 PubMed
16. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003; 63: 7563-7570. PubMed
17. Siedlecki P, Garcia Boy R, Musch T, Brueckner B, Suhai S, Lyko F, Zielenkiewicz P. Discovery of two novel, small-molecule inhibitors of DNA methylation. J Med Chem. 2006; 49: 678-683. doi:10.1021/jm050844z PubMed (Pubitemid 43157497)
18. Segura-Pacheco B, Trejo-Becerril C, Perez-Cardenas E, Taja-Chayeb L, Mariscal I, Chavez A, Acuña C, Salazar AM, Lizano M, Dueñas-Gonzalez A. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin Cancer Res. 2003; 9: 1596-1603. PubMed
19. Song Y, Zhang C. Hydralazine inhibits human cervical cancer cell growth in vitro in association with APC demethylation and re-expression. Cancer Chemother Pharmacol. 2009; 63: 605-613. doi:10.1007/s00280-008-0773-z PubMed
20. Law AY, Lai KP, Ip CK, Wong AS, Wagner GF, Wong CK. Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells. Exp Cell Res. 2008; 314: 1823-1830. doi:10.1016/j.yexcr.2008.03.001 PubMed
21. Wang X, Chao L, Jin G, Ma G, Zang Y, Sun J. Association between CpG island methylation of the WWOX gene and its expression in breast cancers. Tumour Biol. 2009; 30: 8-14. doi:10.1159/000197911 PubMed
22. Bratton AC, Marshall EK. A new coupling component for sulfanilamide determination. J Biol Chem. 1939; 128: 5537-5550.
23. Rao KV, Mitchison DA, Nair NG, Prema K, Tripathy SP. Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. BMJ. 1970; 3: 495-497. doi:10.1136/bmj.3.5721.495 PubMed
24. Reece PA, Cozamanis I, Zacest R. Selective high-performance liquid chromatographic assays for hydralazine and its metabolites in plasma of man. J Chromatogr A. 1980; 181: 427-440. PubMed
25. Arce C, Pérez-Plasencia C, González-Fierro A, de la Cruz-Hernández E, Revilla-Vázquez A, Chávez-Blanco A, Trejo-Becerril C, Pérez-Cárdenas E, Taja-Chayeb L, Bargallo E, Villarreal P, Ramírez T, Vela T, Candelaria M, Camargo MF, Robles E, Dueñas-González A. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS ONE. 2006; 1: e98 doi:10.1371/journal.pone.0000098 PubMed
26. Candelaria M, Gallardo-Rincón D, Arce C, Cetina L, Aguilar-Ponce JL, Arrieta O, González-Fierro A, Chávez-Blanco A, de la Cruz-Hernández E, Camargo MF, Trejo-Becerril C, Pérez- Cárdenas E, Pérez-Plasencia C, Taja-Chayeb L, Wegman-Ostrosky T, Revilla-Vazquez A, Dueñas-González A. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Ann Oncol. 2007; 18: 1529-1538. doi:10.1093/annonc/mdm204 PubMed (Pubitemid 47365487)
27. Candelaria M, Herrera A, Labardini J et al. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial. Ann Hematol. 2011; 90: 379-387.
28. Candelaria M, Cetina L, Pérez-Cárdenas E, de la Cruz-Hernández E, González-Fierro A, Trejo-Becerril C, Taja-Chayeb L, Chanona J, Arias D, Dueñas-González A. Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol. 2010; 31: 386-391. PubMed
29. Coronel J, Cetina L, Pacheco I et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol 2010 Oct 8. (Epub ahead of print).
30. Dueñas-González A, García-López P, Herrera LA, Medina-Franco JL, González-Fierro A, Candelaria M. The prince and the pauper. A tale of anti-cancer targeted agents. Mol Cancer. 2008; 7: 82. doi:10.1186/1476-4598-7-82 PubMed
31. Ludden TM, Rotenberg KS, Ludden LK, Shepherd AM, Woodworth JR. Relative bioavailability of immediate- and sustained-release hydralazine formulations. J Pharm Sci. 1988; 77: 1026-1032. doi:10.1002/jps.2600771208 PubMed
32. Talseth T, Fauchald P, Pape JF. Hydralazine slow-release: observations on serum profile and clinical efficacy in man. Curr Ther Res Clin Exp. 1977; 21: 157-168. PubMed
33. Liedholm H, Wåhlin-Boll E, Hanson A, Melander A. Influence of food on the bioavailability of "real" and "apparent" hydralazine from conventional and slow-release preparations. Drug Nutr Interact. 1982; 1: 293-302. PubMed
34. O'Boyle CP, Kelly J, O'Brien ET, O'Malley K. Once daily slow-release hydralazine in hypertension. Ir Med J. 1981; 74: 115-116. PubMed
35. Melander A, Danielson K, Hanson A, Rudell B, Scherstén B, Thulin T, Wåhlin E. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther. 1977; 22: 104-107. PubMed
36. Reidenberg MM, Drayer D, DeMarco AL, Bello CT. Hydralazine elimination in man. Clin Pharmacol Ther. 1973; 14: 970-977. PubMed
37. Shepherd AM, McNay JL, Ludden TM, Lin MS, Musgrave GE. Plasma concentration and acetylator phenotype determine response to oral hydralazine. Hypertension. 1981; 3: 580-585. PubMed
38. Ludden TM, McNay JL Jr, Shepherd AM, Lin MS. Variability of plasma hydralazine concentrations in male hypertensive patients. Arthritis Rheum. 1981; 24: 987-993. doi:10.1002/art.1780240802 PubMed
39. Safar AM, Macleod S, Klimber V et al. Hydralazine-demethylating systemic therapy for breast cancer. J Clin Oncol. 2006; 24: 13131. abstract.